While gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation) affect many patients initially, severe or persistent symptoms may necessitate dose adjustment, temporary dose reduction, or consideration of alternative therapies
Well-designed clinical trials with depression as a primary outcome measure are needed to establish whether GLP-1 agonists have genuine antidepressant properties independent of their metabolic effects
Health Canada classifies them accordingly, and suppliers operating within Canadian guidelines provide them for non-therapeutic research use
Gulinac M, Miteva DG, Peshevska-Sekulovska M, Novakov IP, Antovic S, Peruhova M, et al
FAQs Can people with diabetes donate blood